Studies in the Society journals

Oral vitamin D3 raises prostate calcitriol levels (level 1 evidence) and modestly lowers both PSA and PTH, justifying continued clinical research. Dennis Wagner, Dominique Trudel, Theodorus Van der Kwast, Larisa Nonn, Angeline Antonio Giangreco, Doris Li, Andre Dias, Monique Cardoza, Sanda Laszlo, Karen Hersey, Laurence Klotz, Antonio Finelli, Neil Fleshner, and Reinhold Vieth. Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients.

ARF has novel function in modulation of AR transactivation in PCa. Wenfu Lu, Yingqiu Xie, Yufang Ma, Robert J. Matusik, and Zhenbang Chen. ARF Represses Androgen Receptor Transactivation in Prostate Cancer.

Cancer-Oncogenes: FRα plays a critical role in mediating the antitumor effect of F-L-DOX. Xiaohai Liu, Sihai Ma, Congxin Dai, Feng Cai, Yong Yao, Yakun Yang, Ming Feng, Kan Deng, Guiling Li, Wenbing Ma, Bing Xin, Wei Lian, Guangya Xiang, Bo Zhang, and Renzhi Wang. Antiproliferative, Antiinvasive, and Proapoptotic Activity of Folate Receptor α-Targeted Liposomal Doxorubicin in Nonfunctional Pituitary Adenoma Cells.

Franck MauvaisJarvis, Deborah J. Clegg, and Andrea L. Hevener. The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis.

You may also like

  • March 2019: Women in Endocrinology

    Gender inequality persists in all sectors of society, including science and medicine disciplines. While female clinicians and researchers are increasing in number[1], they remain underrepresented in scholarly publications and academic positions[2]. Although nearly 50% of medical school graduates are women, they continue to hold fewer senior academic positions and tenured faculty posts than their male…

  • News from ADA 2018

    Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with Canagliflozin Compared to Other Diabetes Medications A new real-world analysis of more than 700,000 U.S. T2D patients found no increased risk of below-knee lower extremity (BKLE) amputation with canagliflozin compared to other sodium glucose…

Find more in